Marlborough, Mass.-based Boston Scientific has agreed to acquire UK-based BTG, which develops products used to treat cancer and vascular diseases, for $4.24 billion. Of BTG’s three key businesses, the largest is its interventional medicine portfolio, which encompasses several peripheral interventional product lines.